Results 111 to 120 of about 25,109 (253)

Supplementary Figure 2 from An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

, 2023
Andrew P. Garner, Carl Uli Bialucha, Elizabeth R. Sprague, Joan T. Garrett, Quan Z. Sheng, Sharon Li, Olga Sineshchekova, Parmita Saxena, Cammie R. Sutton, Dongshu Chen, Yan Chen, Huiqin Wang, Jinsheng Liang, Rita Das, Rebecca Mosher, Jian Gu, Alan Huang, Nicole Haubst, Carolin Zehetmeier, Manuela Haberl, Winfried Elis, Christian Künz, Analeah B. Heidt, Kara Herlihy, Joshua Murtie, Alwin G. Schuller, Carlos L. Arteaga, William R. Sellers, Seth A. Ettenberg   +28 more
openalex   +1 more source

HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells

BMC Cell Biology, 2009
Background Knowledge about signaling pathways is typically compiled based on data gathered using different cell lines. This approach implicitly assumes that the cell line dependence is not important. However, different cell lines do not always respond to
Chrisler William B, Shankaran Harish, Opresko Lee, Zhang Yi, Wiley H Steven, Resat Haluk   +5 more
doaj   +1 more source

Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation

Neoplasia: An International Journal for Oncology Research, 2013
Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to develop novel treatments for cancers that are not eligible for
Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois, Nadège Gaborit, Christel Larbouret, Christophe Le Clorennec, Gaelle Thomas, Wilhem Leconet, Marta Jarlier, Martine Pugnière, Nadia Vié, Bruno Robert, Céline Monnet, Khalil Bouayadi, Hakim Kharrat, Philippe Mondon, André Pèlegrin, Thierry Chardès   +17 more
doaj   +1 more source

Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3 [PDF]

, 2018
Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Dongyun Yang, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Michelle McSkane, W. Zhang, H. Lenz   +15 more
openalex   +1 more source

Data from Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i>-Mutant Thyroid Carcinomas

, 2023
Cristina Montero‐Conde, Sergio Ruiz‐Llorente, José María Domínguez, Jeffrey A. Knauf, Agnès Viale, Eric J. Sherman, Mabel Ryder, Ronald Ghossein, Neal Rosen, James A. Fagin   +9 more
openalex   +1 more source

Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer [PDF]

, 2023
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa   +20 more
openalex   +1 more source

Supplementary Figures 1 through 10 and Supplementary Table 1 from A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers

, 2023
Dhara N. Amin, Deepika Ahuja, Paul Yaswen, Mark M. Moasser   +3 more
openalex   +1 more source

Supplementary Data from Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4⁺ Th1 Responses and Potential Use as a Cancer Vaccine

, 2023
Amrita Basu, Gabriella K. Albert, Sabrina Awshah, Jashodeep Datta, Krithika N. Kodumudi, Corey Gallen, Amber Beyer, Keiran S.M. Smalley, Paulo C. Rodrı́guez, Derek R. Duckett, Peter Forsyth, Aixa Soyano, Gary K. Koski, Ricardo Costa, Heather Han, Hatem Soliman, Marie Catherine Lee, Paweł Kaliński, Brian J. Czerniecki   +18 more
openalex   +2 more sources

1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types [PDF]

, 2023
Zhuolin Li, Chengzhang Shang, Zhenyan Han, Gao An, W. Frank An, Chaoshe Guo, Yi Yang   +6 more
openalex   +1 more source

Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer

Journal of Pharmaceutical Research
Pancreatic cancer (PC) is one of the most lethal tumor malignancies, which has a poor prognosis and can be the cause of death despite tumor removal.
Hosnie Hoseini, Azade Sarani
doaj   +1 more source